Catalyst Wire Dossier Catalyst Wire Dossier

BEXXAR (tositumomab) with I-131

tositumomab with iodine-131 · GlaxoSmithKline
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BEXXAR (tositumomab) with I-131, covering 2012-04-23 to 2012-04-23. Get the full timeline:

Most recent: Clinical Trial Update: A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma [Phase 1]

See pricing